Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$11.11 USD
+0.56 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $11.10 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
COGT 11.11 +0.56(5.31%)
Will COGT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for COGT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COGT
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
COGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for COGT
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation
Cogent Biosciences price target raised by $2 at Baird, here's why
Positive Outlook for Cogent Biosciences Backed by Clinical Trial Progress and Efficient Management
Cogent Biosciences price target lowered by $2 at H.C. Wainwright, here's why
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis